Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BRISTOL MYERS SQUIBB COBMY · Entity 1662 | Director · EVP, CSO & President R&D | June 03, 2013 | June 05, 2013 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BRISTOL MYERS SQUIBB CO
Report date June 03, 2013 · Filed June 05, 2013
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.10 par valueSEC Table I · non-derivative | Direct | 148,221 |
Ending reported balance
After 2013-06-03 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2013-06-03 · Exercise / conversion · Acquired 98,875 · Balance 231,868 Row 2 · 2013-06-03 · Sale · Disposed 83,647 · Balance 148,221 F1: The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $47.83 to $48.62, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. |
| Executive Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.01 · Expires 2017-03-05 | Direct | 25,000 |
Reported balance
After 2013-06-03 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2013-06-03 · Exercise / conversion · Disposed 98,875 · Balance 25,000 F3: Twenty-five percent of the stock option award vested on each of the first, second, third, and fourth anniversaries of the grant date, which was March 6, 2007. |
| Common Stock, $0.10 par valueSEC Table I · non-derivative | IndirectBy BMY Savings & Investment Program | 1,628.06 |
Reported balance
Holding disclosure · report date 2013-06-03 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 1,628.06 F2: Based on a plan statement as of the end of the most recent fiscal quarter. |
| Common Stock, $0.10 par valueSEC Table I · non-derivative | IndirectBy C. Elliott Sigal 2012 Irrevocable Trust | 18,180 |
Reported balance
Holding disclosure · report date 2013-06-03 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 18,180 |
| Common Stock, $0.10 par valueSEC Table I · non-derivative | IndirectBy Ruth L. Sigal Irrevocable Trust | 18,180 |
Reported balance
Holding disclosure · report date 2013-06-03 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 18,180 |
| Common Stock, $0.10 par valueSEC Table I · non-derivative | IndirectBy Sigal Family Investments, LLC | 9,091 |
Reported balance
Holding disclosure · report date 2013-06-03 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 9,091 |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $47.83 to $48.62, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
F2: Based on a plan statement as of the end of the most recent fiscal quarter.
F3: Twenty-five percent of the stock option award vested on each of the first, second, third, and fourth anniversaries of the grant date, which was March 6, 2007.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Mead Johnson Nutrition Co
Report date June 15, 2017 · Filed June 15, 2017
Section 16 reporting ended · disclosed 2017-06-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-06-15 transaction · row 1
1 source rowRow 1 · 2017-06-15 · Disposition to issuer · Disposed 13,721 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated February 10, 2017, by and among Mead Johnson Nutrition Company ("MJN"), Reckitt Benckiser Group plc, and Marigold Merger Sub, Inc. (the "Merger Agreement"), at the effective time of the merger, each share of MJN common stock held by the reporting person was converted into the right to receive a cash payment equal to $90.00 per share. |
| Common StockSEC Table I · non-derivative | IndirectBy Sigal Family Investments, LLC | 0 |
Reported balance
After 2017-06-15 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2017-06-15 · Disposition to issuer · Disposed 2,590 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated February 10, 2017, by and among Mead Johnson Nutrition Company ("MJN"), Reckitt Benckiser Group plc, and Marigold Merger Sub, Inc. (the "Merger Agreement"), at the effective time of the merger, each share of MJN common stock held by the reporting person was converted into the right to receive a cash payment equal to $90.00 per share. |
| Common StockSEC Table I · non-derivative | IndirectBy the C. Elliott Sigal 2012 Irrevocable Trust | 0 |
Reported balance
After 2017-06-15 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2017-06-15 · Disposition to issuer · Disposed 5,180 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated February 10, 2017, by and among Mead Johnson Nutrition Company ("MJN"), Reckitt Benckiser Group plc, and Marigold Merger Sub, Inc. (the "Merger Agreement"), at the effective time of the merger, each share of MJN common stock held by the reporting person was converted into the right to receive a cash payment equal to $90.00 per share. |
| Common StockSEC Table I · non-derivative | IndirectBy the Ruth L. Sigal 2012 Irrevocable Trust | 0 |
Reported balance
After 2017-06-15 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2017-06-15 · Disposition to issuer · Disposed 5,180 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated February 10, 2017, by and among Mead Johnson Nutrition Company ("MJN"), Reckitt Benckiser Group plc, and Marigold Merger Sub, Inc. (the "Merger Agreement"), at the effective time of the merger, each share of MJN common stock held by the reporting person was converted into the right to receive a cash payment equal to $90.00 per share. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2017-06-15 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2017-06-15 · Disposition to issuer · Disposed 1,709 · Balance 0 F2: Each restricted stock unit ("RSU") represents the contingent right to receive one share of common stock. F3: This RSU was originally scheduled to vest on February 28, 2018. Pursuant to the Merger Agreement, at the effective time of the merger, the RSUs held by the reporting person vested and were cancelled in exchange for a lump-sum cash payment equal to the product of (i) the number of shares of common stock subject to such RSU immediately prior to the effective time of the merger and (ii) $90.00 per share. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated February 10, 2017, by and among Mead Johnson Nutrition Company ("MJN"), Reckitt Benckiser Group plc, and Marigold Merger Sub, Inc. (the "Merger Agreement"), at the effective time of the merger, each share of MJN common stock held by the reporting person was converted into the right to receive a cash payment equal to $90.00 per share.
F2: Each restricted stock unit ("RSU") represents the contingent right to receive one share of common stock.
F3: This RSU was originally scheduled to vest on February 28, 2018. Pursuant to the Merger Agreement, at the effective time of the merger, the RSUs held by the reporting person vested and were cancelled in exchange for a lump-sum cash payment equal to the product of (i) the number of shares of common stock subject to such RSU immediately prior to the effective time of the merger and (ii) $90.00 per share.
Spark Therapeutics, Inc.
Report date December 17, 2019 · Filed December 17, 2019
Section 16 reporting ended · disclosed 2019-12-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2019-12-17 transaction · row 1
1 source rowRow 1 · 2019-12-17 · Other · Disposed 14,214 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger, dated February 22, 2019, by and between Spark Therapeutics, Inc. ("Spark"), Roche Holdings, Inc. ("Roche") and 022019 Merger Subsidiary, Inc. ("Merger Sub") (the "Merger Agreement" and the transactions contemplated thereby, the "Merger"), whereby Roche caused Merger Sub to conduct a tender offer for all of the issued and outstanding shares of common stock, par value $0.001 per share, of Spark, at a price of $114.50 per share. On December 17, 2019, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $81.53 · Expires 2028-05-29 | Direct | 0 |
Reported balance
After 2019-12-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-12-17 · Disposition to issuer · Disposed 4,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $50.93 · Expires 2027-05-30 | Direct | 0 |
Reported balance
After 2019-12-17 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-12-17 · Disposition to issuer · Disposed 4,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $56.22 · Expires 2026-05-31 | Direct | 0 |
Reported balance
After 2019-12-17 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-12-17 · Disposition to issuer · Disposed 6,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.45 · Expires 2024-08-11 | Direct | 0 |
Reported balance
After 2019-12-17 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-12-17 · Disposition to issuer · Disposed 17,203 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.45 · Expires 2024-06-10 | Direct | 0 |
Reported balance
After 2019-12-17 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-12-17 · Disposition to issuer · Disposed 25,786 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the Agreement and Plan of Merger, dated February 22, 2019, by and between Spark Therapeutics, Inc. ("Spark"), Roche Holdings, Inc. ("Roche") and 022019 Merger Subsidiary, Inc. ("Merger Sub") (the "Merger Agreement" and the transactions contemplated thereby, the "Merger"), whereby Roche caused Merger Sub to conduct a tender offer for all of the issued and outstanding shares of common stock, par value $0.001 per share, of Spark, at a price of $114.50 per share. On December 17, 2019, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn.
F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 01, 2011 Filed Mar 4, 2011 02:52 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantPerformance Shares · Derivative | 24,031 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-11-008700 · doc4.xml · derivative · entry 8 SIGAL ELLIOT · CIK 0001202294 · Director · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,640 Underlying: Common Stock, $0.10 par value · 24,031 shares Expires not disclosed F10 · derivative.exercise_price: Each performance share converts into one share of common stock upon distribution in the first quarter of 2012. F11 · shares: Consists of performance shares earned under the 2009-2011 Long-Term Performance Award. F10 · derivative.exercise_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2012. F10 · derivative.expiration_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2012. Read SEC document |
| March 01, 2011 Filed Mar 4, 2011 02:52 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantPerformance Shares · Derivative | 28,837 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-11-008700 · doc4.xml · derivative · entry 7 SIGAL ELLIOT · CIK 0001202294 · Director · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,609 Underlying: Common Stock, $0.10 par value · 28,837 shares Expires not disclosed F8 · derivative.exercise_price: Each performance share converts into one share of common stock upon distribution in the first quarter of 2013. F9 · shares: Consists of performance shares earned under the 2010-2012 Long-Term Performance Award. F8 · derivative.exercise_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2013. F8 · derivative.expiration_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2013. Read SEC document |
| March 01, 2011 Filed Mar 4, 2011 02:52 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantPerformance Shares · Derivative | 34,924 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-11-008700 · doc4.xml · derivative · entry 6 SIGAL ELLIOT · CIK 0001202294 · Director · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,772 Underlying: Common Stock, $0.10 par value · 34,924 shares Expires not disclosed F7 · derivative.exercise_price: Each performance share converts into one share of common stock upon distribution in the first quarter of 2011. F1 · shares: Consists of performance shares earned under the 2008-2010 Regular Long-Term Performance Award and the 2008-2010 Special Long-Term Performance Award. F7 · derivative.exercise_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2011. F7 · derivative.expiration_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2011. Read SEC document |
| March 01, 2011 Filed Mar 4, 2011 02:52 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantMarket Share Units · Derivative | 46,858 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-11-008700 · doc4.xml · derivative · entry 5 SIGAL ELLIOT · CIK 0001202294 · Director · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,106 Underlying: Common Stock, $0.10 par value · 46,858 shares Expires not disclosed F5 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock based on the average of the closing share price of the company's common stock on the vesting date and the nine trading days immediately preceding the vesting date. F6 · derivative.exercise_date: Twenty-five percent of the market share unit award will vest on each of the first, second, third and fourth anniversaries of the grant date and will be converted into shares of common stock based on a performance factor. F6 · derivative.expiration_date: Twenty-five percent of the market share unit award will vest on each of the first, second, third and fourth anniversaries of the grant date and will be converted into shares of common stock based on a performance factor. Read SEC document |
| March 01, 2011 Filed Mar 4, 2011 02:52 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 29,920 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-11-008700 · doc4.xml · nonDerivative · entry 3 SIGAL ELLIOT · CIK 0001202294 · Director · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,400 F3 · shares: Shares withheld for payment of taxes upon payout of the 2008-2010 special long-term performance award. Read SEC document |
| March 01, 2011 Filed Mar 4, 2011 02:52 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 20,176 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-11-008700 · doc4.xml · nonDerivative · entry 2 SIGAL ELLIOT · CIK 0001202294 · Director · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,320 F2 · shares: Shares withheld for payment of taxes upon payout of the 2008-2010 regular long-term performance award. Read SEC document |
| March 01, 2011 Filed Mar 4, 2011 02:52 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 116,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-11-008700 · doc4.xml · nonDerivative · entry 1 SIGAL ELLIOT · CIK 0001202294 · Director · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,496 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Consists of performance shares earned under the 2008-2010 Regular Long-Term Performance Award and the 2008-2010 Special Long-Term Performance Award. Read SEC document |
| March 01, 2011 Filed Mar 16, 2011 20:31 UTC Amendment | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 29,920 | $25.58 | $765,353.60 |
DisclosureSEC source: 0001225208-11-009850 · doc4a.xml · nonDerivative · entry 2 SIGAL ELLIOT · CIK 0001202294 · Director · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,400 F3 · shares: This Form 4 is amended to report the correct price for the shares withheld for payment of taxes upon payout of the 2008-2010 special long-term performance award. F2 · balance_after: Includes unvested restricted stock awards. Read SEC document |
| March 01, 2011 Filed Mar 16, 2011 20:31 UTC Amendment | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 20,176 | $25.58 | $516,102.08 |
DisclosureSEC source: 0001225208-11-009850 · doc4a.xml · nonDerivative · entry 1 SIGAL ELLIOT · CIK 0001202294 · Director · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,320 F1 · shares: This Form 4 is amended to report the correct price for the shares withheld for payment of taxes upon payout of the 2008-2010 regular long-term performance award. F2 · balance_after: Includes unvested restricted stock awards. Read SEC document |
| September 20, 2010 Filed Sep 22, 2010 18:38 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 7,726 | $27.81 | $214,860.06 |
DisclosureSEC source: 0001225208-10-021240 · doc4.xml · nonDerivative · entry 1 SIGAL ELLIOT · CIK 0001202294 · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,496 F1 · shares: Shares withheld for payment of taxes upon vesting of restricted stock. F2 · balance_after: Includes unvested restricted stock awards. Read SEC document |
| March 15, 2010 Filed Mar 17, 2010 16:25 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | SaleCommon Stock, $0.10 par value | 47,563 | $25.94 | $1,233,784.22 |
DisclosureSEC source: 0001225208-10-008430 · doc4.xml · nonDerivative · entry 1 SIGAL ELLIOT · CIK 0001202294 · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,222 F1 · balance_after: Includes unvested restricted stock awards. Read SEC document |
| March 07, 2010 Filed Mar 10, 2010 01:33 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 3,554 | $24.60 | $87,428.40 |
DisclosureSEC source: 0001225208-10-007604 · doc4.xml · nonDerivative · entry 3 SIGAL ELLIOT · CIK 0001202294 · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,785 F3 · shares: Shares withheld for payment of taxes upon vesting of restricted stock. F1 · balance_after: Includes unvested restricted stock awards. Read SEC document |
| March 06, 2010 Filed Mar 10, 2010 01:33 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionRestricted Stock Units · Derivative | 6,875 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001225208-10-007604 · doc4.xml · derivative · entry 5 SIGAL ELLIOT · CIK 0001202294 · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,222 Underlying: Common Stock, $0.10 par value · 6,875 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F6 · derivative.exercise_date: One-third of the restricted stock units will vest on each of the third, fourth and fifth anniversaries of the grant date and be converted into shares of common stock. F6 · derivative.expiration_date: One-third of the restricted stock units will vest on each of the third, fourth and fifth anniversaries of the grant date and be converted into shares of common stock. Read SEC document |
| March 06, 2010 Filed Mar 10, 2010 01:33 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 3,187 | $24.60 | $78,400.20 |
DisclosureSEC source: 0001225208-10-007604 · doc4.xml · nonDerivative · entry 2 SIGAL ELLIOT · CIK 0001202294 · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,339 F2 · shares: Shares withheld for payment of taxes upon vesting of restricted stock units. F1 · balance_after: Includes unvested restricted stock awards. Read SEC document |
| March 06, 2010 Filed Mar 10, 2010 01:33 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 6,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-10-007604 · doc4.xml · nonDerivative · entry 1 SIGAL ELLIOT · CIK 0001202294 · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,526 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes unvested restricted stock awards. Read SEC document |
| March 06, 2010 Filed Dec 29, 2011 17:31 UTC Amendment | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionRestricted Stock Units · Derivative | 6,875 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001225208-11-027055 · doc4a.xml · derivative · entry 1 SIGAL ELLIOT · CIK 0001202294 · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,750 Underlying: Common Stock, $0.10 par value · 6,875 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F2 · derivative.exercise_date: One-third of the restricted stock units will vest on each of the third, fourth and fifth anniversaries of the grant date and be converted into shares of common stock. F2 · derivative.expiration_date: One-third of the restricted stock units will vest on each of the third, fourth and fifth anniversaries of the grant date and be converted into shares of common stock. F3 · balance_after: This Form 4 is being amended to reflect the correct number of derivative securities beneficially owned following this reported transaction. The number of derivative securities beneficially owned following the transaction reported for this award in a Form 4 filed on March 8, 2011 was also reported incorrectly. Read SEC document |
| March 02, 2010 Filed Mar 4, 2010 23:57 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionPerformance Shares · Derivative | 72,043 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001225208-10-007220 · doc4.xml · derivative · entry 8 SIGAL ELLIOT · CIK 0001202294 · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,848 Underlying: Common Stock, $0.10 par value · 72,043 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_price: Each performance share converts into one share of common stock upon distribution in the first quarter of 2010. F10 · derivative.exercise_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2010. F10 · derivative.expiration_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2010. Read SEC document |
| March 02, 2010 Filed Mar 4, 2010 23:57 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantPerformance Shares · Derivative | 22,954 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001225208-10-007220 · doc4.xml · derivative · entry 7 SIGAL ELLIOT · CIK 0001202294 · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,891 Underlying: Common Stock, $0.10 par value · 22,954 shares Expires not disclosed F10 · derivative.exercise_price: Each performance share converts into one share of common stock upon distribution in the first quarter of 2010. F11 · shares: Consists of performance shares earned under the 2007-2009 Long-Term Performance Award. F10 · derivative.exercise_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2010. F10 · derivative.expiration_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2010. Read SEC document |
| March 02, 2010 Filed Mar 4, 2010 23:57 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantPerformance Shares · Derivative | 26,772 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001225208-10-007220 · doc4.xml · derivative · entry 6 SIGAL ELLIOT · CIK 0001202294 · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,937 Underlying: Common Stock, $0.10 par value · 26,772 shares Expires not disclosed F8 · derivative.exercise_price: Each performance share converts into one share of common stock upon distribution in the first quarter of 2012. F9 · shares: Consists of performance shares earned under the 2009-2011 Long-Term Performance Award. F8 · derivative.exercise_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2012. F8 · derivative.expiration_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2012. Read SEC document |
| March 02, 2010 Filed Mar 4, 2010 23:57 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantPerformance Shares · Derivative | 39,278 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001225208-10-007220 · doc4.xml · derivative · entry 5 SIGAL ELLIOT · CIK 0001202294 · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,165 Underlying: Common Stock, $0.10 par value · 39,278 shares Expires not disclosed F6 · derivative.exercise_price: Each performance share converts into one share of common stock upon distribution in the first quarter of 2011. F7 · shares: Consists of performance shares earned under the 2008-2010 Regular Long-Term Performance Award and the 2008-2010 Special Long-Term Performance Award. F6 · derivative.exercise_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2011. F6 · derivative.expiration_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2011. Read SEC document |
| March 02, 2010 Filed Mar 4, 2010 23:57 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantMarket Share Units · Derivative | 48,248 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001225208-10-007220 · doc4.xml · derivative · entry 4 SIGAL ELLIOT · CIK 0001202294 · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,248 Underlying: Common Stock, $0.10 par value · 48,248 shares Expires not disclosed F4 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock based on the average of the closing share price of the company?s common stock on the vesting date and the nine trading days immediately preceding the vesting date. F5 · derivative.exercise_date: Twenty-five percent of the market share unit award will vest on each of the first, second, third and fourth anniversaries of the grant date and will be converted into shares of common stock based on a conversion factor. F5 · derivative.expiration_date: Twenty-five percent of the market share unit award will vest on each of the first, second, third and fourth anniversaries of the grant date and will be converted into shares of common stock based on a conversion factor. Read SEC document |
| March 02, 2010 Filed Mar 4, 2010 23:57 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 33,393 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-10-007220 · doc4.xml · nonDerivative · entry 2 SIGAL ELLIOT · CIK 0001202294 · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,651 F2 · shares: Withheld for the payment of taxes upon payout of shares under a Long-Term Performance Award. Read SEC document |
| March 02, 2010 Filed Mar 4, 2010 23:57 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 72,043 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-10-007220 · doc4.xml · nonDerivative · entry 1 SIGAL ELLIOT · CIK 0001202294 · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,044 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Consists of shares earned as long-term performance awards under the 2002 Stock Incentive Plan. Read SEC document |
| March 01, 2010 Filed Mar 3, 2010 21:25 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 2,039 | $24.57 | $50,098.23 |
DisclosureSEC source: 0001225208-10-006844 · doc4.xml · nonDerivative · entry 1 SIGAL ELLIOT · CIK 0001202294 · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,001 F1 · shares: Shares withheld for payment of taxes upon vesting of restricted stock. F2 · balance_after: Includes unvested restricted stock awards. Read SEC document |
| December 23, 2009 Filed Dec 28, 2009 18:57 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | OtherCommon Stock, $0.10 par value | 1,647 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-09-025011 · doc4.xml · nonDerivative · entry 2 SIGAL ELLIOT · CIK 0001202294 · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Indirect · By BMY Savings & Investment Program Disclosed balance after: 1,388.52 F3 · shares: The reporting person directed the Trustee of the Savings and Investment Plan to exchange 1,647 shares of BMS held in the Bristol-Myers Squibb Company Stock Fund into 1,039 shares of MJN to be invested in a new Mead Johnson Nutrition Company Stock Fund. F4 · balance_after: Based on a plan statement as of the end of the most recent fiscal quarter. Read SEC document |
| December 23, 2009 Filed Dec 28, 2009 18:57 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | SaleCommon Stock, $0.10 par value | 12,594 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-09-025011 · doc4.xml · nonDerivative · entry 1 SIGAL ELLIOT · CIK 0001202294 · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,040 F1 · shares: The reporting person exchanged 12,594 shares of Bristol-Myers Squibb common stock for 7,950 shares of Mead Johnson Nutrition Company common stock in an issuer exchange offer. F2 · balance_after: Includes unvested restricted stock awards. Read SEC document |
| December 04, 2009 Filed Dec 16, 2009 21:08 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GiftCommon Stock, $0.10 par value | 5,000 | $25.14 | $125,700.00 |
DisclosureSEC source: 0001225208-09-024569 · doc4.xml · nonDerivative · entry 1 SIGAL ELLIOT · CIK 0001202294 · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,634 F1 · balance_after: Includes unvested restricted stock awards. Read SEC document |
| September 21, 2009 Filed Sep 22, 2009 17:53 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 7,742 | $22.52 | $174,349.84 |
DisclosureSEC source: 0001225208-09-019168 · doc4.xml · nonDerivative · entry 1 SIGAL ELLIOT · CIK 0001202294 · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,634 F1 · shares: Shares withheld for payment of taxes upon vesting of restricted stock. F2 · balance_after: Includes unvested restricted stock awards. Read SEC document |
| April 30, 2009 Filed Apr 30, 2009 20:22 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | PurchaseCommon Stock, $0.10 par value | 15,000 | $19.18 | $287,700.00 |
DisclosureSEC source: 0001225208-09-011049 · doc4.xml · nonDerivative · entry 1 SIGAL ELLIOT · CIK 0001202294 · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,376 F1 · balance_after: Includes unvested restricted stock awards. Read SEC document |
| March 06, 2009 Filed Mar 10, 2009 22:05 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 2,795 | $18.35 | $51,288.25 |
DisclosureSEC source: 0001225208-09-006769 · doc4.xml · nonDerivative · entry 1 SIGAL ELLIOT · CIK 0001202294 · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,708 F1 · shares: Shares withheld for payment of taxes upon vesting of restricted stock. F2 · balance_after: Includes unvested restricted stock awards. Read SEC document |
| March 03, 2009 Filed Mar 5, 2009 22:06 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantRestricted Stock Units · Derivative | 24,877 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001225208-09-006368 · doc4.xml · derivative · entry 3 SIGAL ELLIOT · CIK 0001202294 · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,097 Underlying: Common Stock, $0.10 par value · 24,877 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F1 · derivative.exercise_date: Option is not exercisable until the closing share price of common stock achieves a price of at least 15% above the option grant price and remains at that price for seven consecutive trading days. Option vests 25% of the shares annually, on a cumulative basis, commencing one year after the date of grant, but may not be exercised until the threshold is satisfied. F1 · derivative.expiration_date: Option is not exercisable until the closing share price of common stock achieves a price of at least 15% above the option grant price and remains at that price for seven consecutive trading days. Option vests 25% of the shares annually, on a cumulative basis, commencing one year after the date of grant, but may not be exercised until the threshold is satisfied. Read SEC document |
| March 03, 2009 Filed Mar 5, 2009 22:06 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantRestricted Stock Units · Derivative | 114,220 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001225208-09-006368 · doc4.xml · derivative · entry 2 SIGAL ELLIOT · CIK 0001202294 · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,220 Underlying: Common Stock, $0.10 par value · 114,220 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F1 · derivative.exercise_date: Option is not exercisable until the closing share price of common stock achieves a price of at least 15% above the option grant price and remains at that price for seven consecutive trading days. Option vests 25% of the shares annually, on a cumulative basis, commencing one year after the date of grant, but may not be exercised until the threshold is satisfied. F1 · derivative.expiration_date: Option is not exercisable until the closing share price of common stock achieves a price of at least 15% above the option grant price and remains at that price for seven consecutive trading days. Option vests 25% of the shares annually, on a cumulative basis, commencing one year after the date of grant, but may not be exercised until the threshold is satisfied. Read SEC document |
| March 03, 2009 Filed Mar 5, 2009 22:06 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantExecutive Option (right to buy) · Derivative | 295,497 | $0.00 Strike: $17.51 | $0.00 |
DisclosureSEC source: 0001225208-09-006368 · doc4.xml · derivative · entry 1 SIGAL ELLIOT · CIK 0001202294 · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 295,497 Underlying: Common Stock, $0.10 par value · 295,497 shares Expires 2019-03-02 F1 · derivative.exercise_date: Option is not exercisable until the closing share price of common stock achieves a price of at least 15% above the option grant price and remains at that price for seven consecutive trading days. Option vests 25% of the shares annually, on a cumulative basis, commencing one year after the date of grant, but may not be exercised until the threshold is satisfied. Read SEC document |
| March 02, 2009 Filed Mar 3, 2009 22:15 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 980 | $17.74 | $17,385.20 |
DisclosureSEC source: 0001225208-09-005823 · doc4.xml · nonDerivative · entry 2 SIGAL ELLIOT · CIK 0001202294 · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,503 F1 · shares: Shares withheld for payment of taxes upon vesting of restricted stock. F2 · balance_after: Includes unvested restricted stock awards. Read SEC document |
| March 01, 2009 Filed Mar 3, 2009 22:15 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 2,096 | $18.41 | $38,587.36 |
DisclosureSEC source: 0001225208-09-005823 · doc4.xml · nonDerivative · entry 1 SIGAL ELLIOT · CIK 0001202294 · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,483 F1 · shares: Shares withheld for payment of taxes upon vesting of restricted stock. F2 · balance_after: Includes unvested restricted stock awards. Read SEC document |
| February 19, 2009 Filed Feb 23, 2009 21:20 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantPerformance Shares · Derivative | 26,709 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001225208-09-004534 · doc4.xml · derivative · entry 4 SIGAL ELLIOT · CIK 0001202294 · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,887 Underlying: Common Stock, $0.10 par value · 26,709 shares Expires not disclosed F6 · derivative.exercise_price: Each performance share is converted into one share of common stock upon distribution in the first quarter of 2010. F7 · shares: Consists of performance shares earned under the 2007-2009 Long-Term Performance Award. F6 · derivative.exercise_date: Each performance share is converted into one share of common stock upon distribution in the first quarter of 2010. F6 · derivative.expiration_date: Each performance share is converted into one share of common stock upon distribution in the first quarter of 2010. Read SEC document |
| February 19, 2009 Filed Feb 23, 2009 21:20 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantPerformance Shares · Derivative | 41,798 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001225208-09-004534 · doc4.xml · derivative · entry 3 SIGAL ELLIOT · CIK 0001202294 · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,178 Underlying: Common Stock, $0.10 par value · 41,798 shares Expires not disclosed F4 · derivative.exercise_price: Each performance share is converted into one share of common stock upon distribution in the first quarter of 2011. F5 · shares: Consists of performance shares earned under the 2008-2010 Regular Long-Term Performance Award and the 2008-2010 Special Long-Term Performance Award. F4 · derivative.exercise_date: Each performance share is converted into one share of common stock upon distribution in the first quarter of 2011. F4 · derivative.expiration_date: Each performance share is converted into one share of common stock upon distribution in the first quarter of 2011. Read SEC document |
| February 19, 2009 Filed Feb 23, 2009 21:20 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantCommon Stock, $0.10 par value | 28,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-09-004534 · doc4.xml · nonDerivative · entry 1 SIGAL ELLIOT · CIK 0001202294 · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,579 F1 · shares: Consists of shares earned as long-term performance awards under the 2002 Stock Incentive Plan. F2 · balance_after: Includes unvested restricted stock awards. Read SEC document |
| February 19, 2009 Filed Mar 24, 2009 19:43 UTC Amendment | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 13,332 | $20.51 | $273,439.32 |
DisclosureSEC source: 0001225208-09-007611 · doc4a.xml · nonDerivative · entry 1 SIGAL ELLIOT · CIK 0001202294 · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,247 F1 · kind: This Form 4 is being amended to reflect the shares withheld for taxes upon the distribution of a performance share award. F2 · shares: Shares withheld for payment of taxes upon distribution of long-term performance award. F3 · balance_after: Includes unvested restricted stock awards. Read SEC document |
| September 19, 2008 Filed Sep 23, 2008 20:03 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 7,742 | $21.00 | $162,582.00 |
DisclosureSEC source: 0001225208-08-015045 · doc4.xml · nonDerivative · entry 1 SIGAL ELLIOT · CIK 0001202294 · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,879 F1 · shares: Shares withheld for payment of taxes upon vesting of restricted stock. F2 · balance_after: Includes unvested restricted stock awards. Read SEC document |
| September 10, 2008 Filed Sep 12, 2008 18:32 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 3,872 | $21.67 | $83,906.24 |
DisclosureSEC source: 0001225208-08-014722 · doc4.xml · nonDerivative · entry 1 SIGAL ELLIOT · CIK 0001202294 · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,621 F1 · shares: Shares withheld for payment of taxes upon vesting of restricted stock. F2 · balance_after: Includes unvested restricted stock awards. Read SEC document |
| March 04, 2008 Filed Mar 6, 2008 22:04 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | GrantRestricted Stock Units · Derivative | 22,358 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-08-000100 · sig841.xml · derivative · entry 2 SIGAL ELLIOT · CIK 0001202294 · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,358 Underlying: Common Stock, $0.10 par value · 22,358 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F3 · derivative.exercise_date: One-third of the restricted stock units will vest on each of the third, fourth and fifth anniversaries of the grant date and be converted into shares of common stock. F3 · derivative.expiration_date: One-third of the restricted stock units will vest on each of the third, fourth and fifth anniversaries of the grant date and be converted into shares of common stock. Read SEC document |
| March 04, 2008 Filed Mar 6, 2008 22:04 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | GrantExecutive Option (right to buy) · Derivative | 305,909 | $0.00 Strike: $22.14 | $0.00 |
DisclosureSEC source: 0000014272-08-000100 · sig841.xml · derivative · entry 1 SIGAL ELLIOT · CIK 0001202294 · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 305,909 Underlying: Common Stock, $0.10 par value · 305,909 shares Expires 2018-03-03 F1 · derivative.exercise_date: Option is not exercisable until the closing share price of common stock achieves a price of at least 15% above the option grant price and remains at that price for seven consecutive trading days. Shares vest 25% per year, on a cumulative basis, commencing one year after the grant date. Read SEC document |
| March 04, 2008 Filed Feb 18, 2009 00:23 UTC Amendment | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantPerformance Shares · Derivative | 22,380 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-09-000017 · primary_doc.xml · derivative · entry 1 SIGAL ELLIOT · CIK 0001202294 · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,380 Underlying: Common Stock $0.10 par value · 22,380 shares Expires not disclosed F1 · derivative.exercise_price: (1) Each performance share converts into one share of common stock upon distribution during the first quarter of 2010. F1 · derivative.exercise_date: (1) Each performance share converts into one share of common stock upon distribution during the first quarter of 2010. F1 · derivative.expiration_date: (1) Each performance share converts into one share of common stock upon distribution during the first quarter of 2010. Read SEC document |
| March 02, 2008 Filed Mar 4, 2008 18:35 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 925 | $22.61 | $20,914.25 |
DisclosureSEC source: 0000014272-08-000076 · sig827.xml · nonDerivative · entry 2 SIGAL ELLIOT · CIK 0001202294 · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,493 F1 · shares: Shares withheld for payment of taxes upon vesting of restricted stock. F2 · balance_after: Includes unvested restricted stock awards. Read SEC document |
| March 01, 2008 Filed Mar 4, 2008 18:35 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 1,981 | $22.61 | $44,790.41 |
DisclosureSEC source: 0000014272-08-000076 · sig827.xml · nonDerivative · entry 1 SIGAL ELLIOT · CIK 0001202294 · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,418 F1 · shares: Shares withheld for payment of taxes upon vesting of restricted stock. F2 · balance_after: Includes unvested restricted stock awards. Read SEC document |
| November 01, 2007 Filed Nov 2, 2007 21:02 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 3,872 | $29.16 | $112,907.52 |
DisclosureSEC source: 0000014272-07-000205 · sig764.xml · nonDerivative · entry 1 SIGAL ELLIOT · CIK 0001202294 · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,410 F1 · shares: Shares withheld for payment of taxes upon vesting of restricted stock. F2 · balance_after: Includes unvested restricted stock awards. Read SEC document |
| September 10, 2007 Filed Sep 12, 2007 20:06 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 3,871 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-07-000179 · sig753.xml · nonDerivative · entry 1 SIGAL ELLIOT · CIK 0001202294 · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,282 F1 · shares: Shares withheld for payment of taxes upon vesting of restricted stock. F2 · balance_after: Includes unvested restricted stock awards. Read SEC document |
| September 10, 2007 Filed Jan 15, 2008 22:05 UTC Amendment | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 3,882 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-08-000021 · sig775.xml · nonDerivative · entry 1 SIGAL ELLIOT · CIK 0001202294 · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,271 F1 · shares: This form is being amended to correct the number of shares withheld for payment of taxes upon vesting of restricted stock. F2 · balance_after: Includes unvested restricted stock awards. Read SEC document |
| March 06, 2007 Filed Mar 8, 2007 22:18 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | GrantRestricted Stock Units · Derivative | 20,625 | $0.00 Strike: $27.01 | $0.00 |
DisclosureSEC source: 0000014272-07-000082 · sig684.xml · derivative · entry 5 SIGAL ELLIOT · CIK 0001202294 · EVP, CSO & President PRI 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,625 Underlying: Common Stock, $0.10 par value · 20,625 shares Expires 2017-03-05 F6 · derivative.exercise_date: Consists of restricted stock units with one-third vesting on each of the third, fourth and fifth anniversaries of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.